ROCHE ACCELERATES SAQUINAVIR FILING

12 June 1994

Roche is preparing to file an accelerated approval New Drug Application for the proteinase inhibitor saquinavir, based on results of a Phase II trial of the compound in combination with Wellcome's Retrovir (zidovudine) and its Hivid (zalcitabine) drug. The company is currently in discussion with the US Food and Drug Administration to see if an accelerated approval is appropriate. Roche is also to investigate a triple combination therapy as part of its Phase III program.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight